Gsk (GLAXF) Invested Capital (2014 - 2025)

Gsk's Invested Capital history runs 12 years deep, the most recent figure standing at $71.4 billion for Q4 2025.

• In Q4 2025, Invested Capital rose 10.28% year-over-year to $71.4 billion; the TTM figure through Dec 2025 stood at $71.4 billion (up 10.28% YoY), while the FY2025 annual figure was $70.7 billion, up 9.76% from the prior year.
• Invested Capital was $71.4 billion for Q4 2025 at Gsk, up from $64.7 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $71.4 billion in Q4 2025 to a low of $32.6 billion in Q4 2022.
• Historically, Invested Capital has averaged $50.2 billion across 5 years, with a median of $47.0 billion in 2021.
• The sharpest annual moves came in 2022 and 2024: Invested Capital slumped 30.69% in 2022, then soared 83.66% in 2024.
• A 5-year view of Invested Capital shows it stood at $47.0 billion in 2021, then plunged by 30.69% to $32.6 billion in 2022, then advanced by 8.07% to $35.2 billion in 2023, then jumped by 83.66% to $64.7 billion in 2024, then grew by 10.28% to $71.4 billion in 2025.
• The last three Invested Capital figures came in at $71.4 billion (Q4 2025), $64.7 billion (Q4 2024), and $35.2 billion (Q4 2023), per Business Quant data.